Literature DB >> 15509682

Serological speciation of human schistosome infections by ELISA with a panel of three antigens.

P Turner1, K Lalloo, J Bligh, M Armstrong, C J M Whitty, M J Doenhoff, P L Chiodini.   

Abstract

AIMS: To find out whether serology can reliably speciate human schistosomiasis using a simple enzyme linked immunosorbent assay (ELISA) technique.
METHODS: Stored sera from 66 patients with microscopically confirmed schistosomiasis were subjected to ELISA using a panel of three antigens, namely: unfractionated Schistosoma mansoni soluble egg antigen (SEA); CEF6, a cationic fraction of SEA; and crude S margrebowiei egg antigen, prepared from an animal schistosome closely related to S haematobium.
RESULTS: The optical densities (ODs) obtained using CEF6 as antigen were significantly higher in sera from S mansoni infected patients than in sera from S haematobium infected patients (median OD, 0.810 v 0.595). Using S margrebowiei egg antigen, the optical densities were significantly higher in S haematobium sera than in S mansoni sera (median OD, 0.794 v 0.544). There was no significant difference in optical densities between S mansoni and S haematobium sera using SEA (median OD, 0.725 v 0.737). The ratio of ODs (CEF6 to S margrebowiei egg antigen) was calculated: a ratio of >1 indicated S mansoni infection (sensitivity, 88%) and a ratio of <1 indicated S haematobium infection (sensitivity, 84%). The odds ratio for S haematobium having an OD ratio of <1 was 36.8 (95% confidence interval, 7.0 to 194).
CONCLUSIONS: The identity of the infecting species of schistosome can be determined using the panel of antigens described. SEA should be used to screen serum samples, and the CEF6 : S margrebowiei egg antigen ELISA optical density ratio can be used where serological speciation is required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509682      PMCID: PMC1770487          DOI: 10.1136/jcp.2003.014779

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  An evaluation of the ELISA for schistosomiasis in a hospital population.

Authors:  J H Tosswill; D S Ridley
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Identification and partial purification of an antigen (omega 1) from Schistosoma mansoni eggs which is putatively hepatotoxic in T-cell deprived mice.

Authors:  D W Dunne; S Lucas; Q Bickle; S Pearson; L Madgwick; J Bain; M J Doenhoff
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

4.  Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country.

Authors:  C J Whitty; D C Mabey; M Armstrong; S G Wright; P L Chiodini
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

Review 5.  Diagnosis of schistosomiasis: antibody detection, with notes on parasitological and antigen detection methods.

Authors:  J V Hamilton; M Klinkert; M J Doenhoff
Journal:  Parasitology       Date:  1998       Impact factor: 3.234

6.  Preliminary observations on the distribution, definitive hosts and possible relation with other schistosomes, of Schistosoma margrebowiei, Le Roux, 1933 and Schistosoma leiperi, Le Roux, 1955.

Authors:  R J Pitchford
Journal:  J Helminthol       Date:  1976-06       Impact factor: 2.170

7.  Seroepidemiology and serodiagnosis of schistosomiasis in Kenya using crude and purified egg antigens of Schistosoma mansoni in ELISA.

Authors:  M J Doenhoff; A E Butterworth; R J Hayes; R F Sturrock; J H Ouma; D Koech; M Prentice; J Bain
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

Review 8.  Immunodiagnosis of schistosomiasis. Screen with FAST-ELISA and confirm with immunoblot.

Authors:  V C Tsang; P P Wilkins
Journal:  Clin Lab Med       Date:  1991-12       Impact factor: 1.935

9.  The purification, characterization, serological activity and hepatotoxic properties of two cationic glycoproteins (alpha 1 and omega 1) from Schistosoma mansoni eggs.

Authors:  D W Dunne; F M Jones; M J Doenhoff
Journal:  Parasitology       Date:  1991-10       Impact factor: 3.234

10.  Schistosomiasis and soil-transmitted helminth infections: forging control efforts.

Authors:  Lorenzo Savioli; Sally Stansfield; Donald A P Bundy; Arlene Mitchell; Rita Bhatia; Dirk Engels; Antonio Montresor; Maria Neira; Ali Mohammed Shein
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Nov-Dec       Impact factor: 2.184

View more
  4 in total

1.  Comparative evaluation of Schistosoma mansoni, Schistosoma intercalatum, and Schistosoma haematobium alkaline phosphatase antigenicity by the alkaline phosphatase immunoassay (APIA).

Authors:  I M Cesari; D E Ballén; L Mendoza; A Ferrer; J-P Pointier; M Kombila; D Richard-Lenoble; A Théron
Journal:  Parasitol Res       Date:  2014-01-23       Impact factor: 2.289

2.  Comparative analysis of the diagnostic performance of adult, cercarial and egg antigens assessed by ELISA, in the diagnosis of chronic human Schistosoma mansoni infection.

Authors:  Rania Mohammad Sarhan; Heba AbdelKader Aminou; Ghada Abdel Rahman Saad; Ossama Ashraf Ahmed
Journal:  Parasitol Res       Date:  2014-07-16       Impact factor: 2.289

3.  Comparison of Schistosoma mansoni soluble cercarial antigens and soluble egg antigens for serodiagnosing schistosome infections.

Authors:  Huw Smith; Mike Doenhoff; Cara Aitken; Wendi Bailey; Minjun Ji; Emily Dawson; Henk Gilis; Grant Spence; Claire Alexander; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2012-09-13

4.  New approaches with different types of circulating cathodic antigen for the diagnosis of patients with low Schistosoma mansoni load.

Authors:  Rafaella Grenfell; Donald A Harn; Smanla Tundup; Akram Da'dara; Liliane Siqueira; Paulo Marcos Zech Coelho
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.